Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Delivering base editors to the liver and lungs in alpha-1 antitrypsin deficiency

We developed Dual Selective Organ-Targeting Lipid Nanoparticles (Dual SORT LNPs) capable of delivering base editors to multiple organs. Base editor Dual SORT LNPs corrected disease-causing mutations in both the liver and lungs, the primary organs affected in alpha-1 antitrypsin deficiency.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Dual SORT LNPs effectively addressed toxicities in both the liver and lungs.

References

  1. Strnad, P., McElvaney, N. G. & Lomas, D. A. Alpha1-antitrypsin deficiency. N. Engl. J. Med. 382, 1443–1455 (2020). A review article on AATD.

    Article  CAS  PubMed  Google Scholar 

  2. Zamora, M. R. & Ataya, A. Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency. Ther. Adv. Chronic Dis. 12, (Suppl.) 20406223211002988 (2021). A review article that presents current treatment options for AATD.

  3. Stiles, K. M. et al. Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease. Chronic Obstr. Pulm. Dis. 5, 244–257 (2018). A review article on gene therapy for AATD.

    PubMed  PubMed Central  Google Scholar 

  4. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020). This paper reports the LNP SORT methodology.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Beam Therapeutics. A phase 1/2 dose-exploration and dose-expansion study to evaluate the safety and efficacy of BEAM-302 in adult patients with alpha-1 antitrypsin deficiency (AATD)-associated lung disease and/or liver disease. https://clinicaltrials.gov/study/NCT06389877 (2025). A clinical study that presents base editor AATD treatment.

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Kim, M. et al. Dual SORT LNPs for multi-organ base editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02675-z (2025).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Delivering base editors to the liver and lungs in alpha-1 antitrypsin deficiency. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02705-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-025-02705-w

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research